Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Director Sells $4,223,373.00 in Stock

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Director Biotech Aps Wg sold 116,700 shares of Y-mAbs Therapeutics stock in a transaction on Wednesday, June 9th. The stock was sold at an average price of $36.19, for a total transaction of $4,223,373.00. Following the sale, the director now owns 4,306,394 shares in the company, valued at approximately $155,848,398.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Biotech Aps Wg also recently made the following trade(s):

  • On Monday, June 7th, Biotech Aps Wg sold 72,400 shares of Y-mAbs Therapeutics stock. The shares were sold at an average price of $34.15, for a total value of $2,472,460.00.
  • On Friday, June 4th, Biotech Aps Wg sold 3,841 shares of Y-mAbs Therapeutics stock. The shares were sold at an average price of $34.03, for a total value of $130,709.23.

Y-mAbs Therapeutics stock opened at $37.53 on Friday. The firm has a 50-day simple moving average of $31.34. Y-mAbs Therapeutics, Inc. has a 12-month low of $24.77 and a 12-month high of $55.22. The company has a market capitalization of $1.64 billion, a PE ratio of -23.90 and a beta of 1.22.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings results on Thursday, May 6th. The company reported $0.75 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.61 by $0.14. As a group, analysts forecast that Y-mAbs Therapeutics, Inc. will post -1.06 EPS for the current fiscal year.

YMAB has been the subject of a number of analyst reports. HC Wainwright lifted their price objective on Y-mAbs Therapeutics from $65.00 to $70.00 and gave the company a “buy” rating in a report on Monday, March 1st. Wedbush cut their price objective on Y-mAbs Therapeutics from $67.00 to $52.00 and set an “outperform” rating for the company in a report on Wednesday, April 21st. Bank of America raised Y-mAbs Therapeutics from a “neutral” rating to a “buy” rating in a report on Friday, May 7th. Zacks Investment Research cut Y-mAbs Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, February 24th. Finally, JPMorgan Chase & Co. reissued an “overweight” rating and set a $52.00 price objective on shares of Y-mAbs Therapeutics in a report on Monday, March 22nd. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $54.38.

A number of large investors have recently made changes to their positions in the business. BlackRock Inc. raised its holdings in Y-mAbs Therapeutics by 4.4% during the 1st quarter. BlackRock Inc. now owns 2,524,776 shares of the company’s stock worth $76,350,000 after purchasing an additional 106,196 shares during the last quarter. Artisan Partners Limited Partnership raised its holdings in Y-mAbs Therapeutics by 25.8% during the 1st quarter. Artisan Partners Limited Partnership now owns 1,317,900 shares of the company’s stock worth $39,853,000 after purchasing an additional 270,484 shares during the last quarter. Alliancebernstein L.P. raised its holdings in Y-mAbs Therapeutics by 21.9% during the 1st quarter. Alliancebernstein L.P. now owns 1,231,338 shares of the company’s stock worth $37,236,000 after purchasing an additional 221,019 shares during the last quarter. First Light Asset Management LLC raised its holdings in Y-mAbs Therapeutics by 48.5% during the 1st quarter. First Light Asset Management LLC now owns 944,253 shares of the company’s stock worth $28,554,000 after purchasing an additional 308,601 shares during the last quarter. Finally, Ashford Capital Management Inc. raised its holdings in Y-mAbs Therapeutics by 131.6% during the 1st quarter. Ashford Capital Management Inc. now owns 508,083 shares of the company’s stock worth $15,364,000 after purchasing an additional 288,664 shares during the last quarter. 60.76% of the stock is owned by hedge funds and other institutional investors.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma.

Recommended Story: How much can an individual set aside as a catch-up contribution?

Insider Buying and Selling by Quarter for Y-mAbs Therapeutics (NASDAQ:YMAB)

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.